Sugi Predict

Sugi Predict / Compounds / SCHEMBL303956

SCHEMBL303956

SCHEMBL303956

CC(C)(C)OC(=O)NC(CCN)C(=O)O

nearest known ligand 0.49

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ CTSK P43235 7/20 0.49
▸ CTSS P25774 6/20 0.49
▸ MEN1 O00255 1/20 0.46
▸ GAA P10253 1/20 0.46
▸ KMT2A Q03164 1/20 0.46
▸ PPARA Q07869 7/20 0.46
▸ PPARG P37231 6/20 0.46
▸ CTSL P07711 1/20 0.46
▸ CTSB P07858 1/20 0.46
▸ ACE P12821 1/20 0.45
▸ PPARD Q03181 2/20 0.44
▸ CA1 P00915 1/20 0.44
▸ CA2 P00918 1/20 0.44
▸ CA7 P43166 1/20 0.44
▸ IDO1 P14902 1/20 0.42
▸ ITGB3 P05106 1/20 0.42
▸ ITGA2B P08514 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2612149 1.00 CTSK (0.49) CTSKCTSSMEN1GAAKMT2A
SCHEMBL303955 1.00 CTSK (0.49) CTSKCTSSMEN1GAAKMT2A
Hydrochloric Acid SCHEMBL1644095 0.98 CTSK (0.48) CTSKCTSSMEN1GAAKMT2A
Hydrochloric Acid SCHEMBL1644093 0.98 CTSK (0.48) CTSKCTSSMEN1GAAKMT2A
SCHEMBL205184 0.90 CTSK (0.51) CTSKCTSSMEN1GAAKMT2A
SCHEMBL1487792 0.90 CTSK (0.51) CTSKCTSSMEN1GAAKMT2A
SCHEMBL205183 0.90 CTSK (0.51) CTSKCTSSMEN1GAAKMT2A
Hydrochloric Acid SCHEMBL28031453 0.89 CTSK (0.50) CTSKCTSSMEN1GAAKMT2A
Hydrochloric Acid SCHEMBL2191093 0.89 CTSK (0.50) CTSKCTSSMEN1GAAKMT2A
SCHEMBL376450 0.89 FOLH1 (0.53) CTSKCTSSMEN1GAAKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 276 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4540267-B1 CYCLIC PEPTIDES FOR TRAPPING INTERLEUKIN-1 BETA MERCK SHARP & DOHME LLC (US) 2026-04-15 — — EP disclosed
US-20250352549-A1 SUBSTITUTED HETEROCYCLIC COMPOUND DERIVATIVES AND THEIR PHARMACEUTICAL USE AVELOS THERAPEUTICS INC. (KR) 2025-11-20 — — US disclosed
EP-4634192-A1 SUBSTITUTED HETEROCYCLIC COMPOUND DERIVATIVES AND THEIR PHARMACEUTICAL USE Avelos Therapeutics Inc. (KR) 2025-10-22 — — EP disclosed
US-20250205348-A1 NOVEL PEPTIDIC LINKERS AND CRYPTOPHYCIN CONJUGATES, THEIR PREPARATION AND THEIR THERAPEUTIC USE SANOFI (FR) 2025-06-26 — — US disclosed
WO-2024128741-A9 SUBSTITUTED HETEROCYCLIC COMPOUND DERIVATIVES AND THEIR PHARMACEUTICAL USE AVELOS THERAPEUTICS INC. (KR) 2025-05-30 — — WO disclosed
EP-4540267-A1 CYCLIC PEPTIDES FOR TRAPPING INTERLEUKIN-1 BETA Merck Sharp & Dohme LLC (US) 2025-04-23 — — EP disclosed
US-20250115561-A1 BIPHENYL-SUBSTITUTED EPITHELIAL SODIUM CHANNEL BLOCKING COMPOUNDS PARION SCIENCES, INC. (US) 2025-04-10 — — US disclosed
WO-2025030117-A1 FERROPTOSIS INDUCERS ARPEGGIO BIOSCIENCES, INC. (US) 2025-02-06 — — WO disclosed
EP-4469441-A1 BIPHENYL-SUBSTITUTED EPITHELIAL SODIUM CHANNEL BLOCKING COMPOUNDS Parion Sciences, Inc. (US) 2024-12-04 — — EP disclosed
WO-2024128741-A1 SUBSTITUTED HETEROCYCLIC COMPOUND DERIVATIVES AND THEIR PHARMACEUTICAL USE AVELOS THERAPEUTICS INC. (KR) 2024-06-20 — — WO disclosed
US-20080299075-A1 HEPATITIS C VIRUS INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2008-12-04 — — US disclosed
WO-2008144380-A1 HEPATITIS C VIRUS INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2008-11-27 — — WO disclosed
CN-101263156-A Novel macrocyclic inhibitors of hepatitis C virus replication INTERMUNE INC (US) 2008-09-10 — — CN disclosed
US-20080050336-A1 Hepatitis C Virus Inhibitors BRISTOL-MYERS SQUIBB COMPANY 2008-02-28 — — US disclosed
US-20080044379-A1 Hepatitis C Virus Inhibitors BRISTOL-MYERS SQUIBB COMPANY 2008-02-21 — — US disclosed
US-20080044380-A1 Hepatitis C Virus Inhibitors BRISTOL-MYERS SQUIBB COMPANY 2008-02-21 — — US disclosed
WO-2004076434-A1 DIPEPTIDYL PEPTIDASE INHIBITORS AIC (BE) 2004-09-10 — — WO disclosed
US-5610141-A CELL DIVISION STIMULANT NYCOMED IMAGING AS (NO) 1997-03-11 — — US disclosed
EP-0673388-A1 DOUBLE CHAIN PEPTIDE COMPOUNDS HAVING HEMOREGULATORY ACTIVITY NYCOMED IMAGING AS (NO) 1995-09-27 — — EP disclosed
WO-1993024523-A1 DOUBLE CHAIN PEPTIDE COMPOUNDS HAVING HEMOREGULATORY ACTIVITY HAFSLUND NYCOMED AS (NO) 1993-12-09 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250115561-A1 BIPHENYL-SUBSTITUTED EPITHELIAL SODIUM CHANNEL BLOCKING COMPOUNDS CFTR, SCNN1B, SCNN1G CTSK 2598/4885CTSS 1501/4885MEN1 4045/4885
US-20080050336-A1 Hepatitis C Virus Inhibitors HAVCR2, PYGL, HCCS CTSK 789/4885CTSS 864/4885MEN1 4867/4885
US-20080299075-A1 HEPATITIS C VIRUS INHIBITORS HAVCR2, PYGL, HCCS CTSK 789/4885CTSS 864/4885MEN1 4867/4885
US-20250352549-A1 SUBSTITUTED HETEROCYCLIC COMPOUND DERIVATIVES AND THEIR PHARMACEUTICAL USE MAST1, MAST3, MAST4 CTSK 493/4885CTSS 1211/4885MEN1 1228/4885
US-20080044379-A1 Hepatitis C Virus Inhibitors HAVCR2, PYGL, HCCS CTSK 789/4885CTSS 864/4885MEN1 4867/4885
US-20080044380-A1 Hepatitis C Virus Inhibitors HAVCR2, PYGL, HCCS CTSK 789/4885CTSS 864/4885MEN1 4867/4885
US-20250205348-A1 NOVEL PEPTIDIC LINKERS AND CRYPTOPHYCIN CONJUGATES, THEIR PREPARATION AND THEIR THERAPEUTIC USE RPN1, CLSPN, FRG1 CTSK 3059/4885CTSS 2762/4885MEN1 594/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.